SubsidieMeesters logoSubsidieMeesters
ProjectenRegelingenAnalyses

Molecules for Nociceptor Force Transduction

This project aims to identify and target specific molecules involved in nociceptor force transduction to develop new pain therapies.

Subsidie
€ 2.500.000
2024

Projectdetails

Introduction

Pain results from activation of the nociceptive sensory system, which is built upon the primary afferent nociceptor, a type of sensory neuron specialized to detect, code, and relay information about potentially or actually damaging stimuli. Humans lacking properly functioning nociceptors never experience pain and have reduced life expectancy, suffering severe disability.

Nociceptor Function

Nociceptors detect sustained force into ranges that are potentially damaging, and sustained nociceptor activation will always lead to pain. It has been assumed that mechanical force transduced by nociceptors requires mechanically activated ion channels in the nociceptor membrane.

Recent Findings

However, recent data suggests that sensory Schwann cells that wrap the nociceptor ending also participate in force transduction. The aim of this proposal is to identify molecules specifically involved in nociceptor force transduction at this neuroglial site.

Identified Molecules

We have already identified:

  1. An ion channel (Tmem87a/ELKIN1)
  2. An extracellular tether protein (TENM4)

These molecules are involved in nociceptor force transduction. In addition, STOML3 modulates ELKIN1 function and can sensitize almost all nociceptors to mechanical force.

Research Approach

The identification of a set of molecules involved in force transduction (ELKIN1/TENM4/STOML3) will allow us to design “guilt by association” approaches to identify new players. We will use:

  • Ultra-low input spatial proteomics
  • BioID
  • High throughput electrophysiological screening

to achieve this aim.

Genetic Strategies

We have designed novel genetic strategies to interrogate the function of candidate proteins in nociceptor force transduction, with timescales ranging from weeks to minutes.

Project Impact

This ambitious and challenging project promises to deliver novel molecular targets that can be used to specifically target nociceptor force transduction. Specific targeting of nociceptor force transduction could be a powerful new way to treat multiple pain types poorly served by existing therapies.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 2.500.000
Totale projectbegroting€ 2.500.000

Tijdlijn

Startdatum1-7-2024
Einddatum30-6-2029
Subsidiejaar2024

Partners & Locaties

Projectpartners

  • MAX DELBRUECK CENTRUM FUER MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFT (MDC)penvoerder

Land(en)

Germany

Inhoudsopgave

European Research Council

Financiering tot €10 miljoen voor baanbrekend frontier-onderzoek via ERC-grants (Starting, Consolidator, Advanced, Synergy, Proof of Concept).

Bekijk regeling

Vergelijkbare projecten binnen European Research Council

ProjectRegelingBedragJaarActie

Uncovering the cortical cellular basis of specificity and chronicity of pain

This project aims to identify and manipulate neocortical neuronal ensembles to understand their role in pain perception and develop non-invasive methods for chronic pain relief.

ERC Advanced...€ 2.468.700
2025
Details

Descending control of pain

DescendPain aims to classify RVM neuron types and uncover how brain modulation of pain varies with affective states, potentially transforming pain treatment strategies.

ERC Advanced...€ 2.500.000
2023
Details

Engineering synthetic mechanotransduction through nucleocytoplasmic transport

This project aims to engineer synthetic mechanotransduction in cells to control gene expression through mechanical signals, enhancing our understanding of cell behavior in response to tissue mechanics.

ERC Advanced...€ 2.499.875
2023
Details

PERSONALIZED NON-INVASIVE NEUROMODULATION IN PAIN

PersoNINpain aims to personalize chronic pain treatment by using brain connectivity metrics to optimize non-invasive neuromodulation techniques like rTMS for individual patients.

ERC Consolid...€ 1.618.278
2023
Details

Chronic PAIN eradiCAtion by taRgeting Schwann cElls

PAIN-CARE aims to develop Schwann cell selective analgesic drugs to effectively treat chronic pain with fewer side effects than current NSAIDs and opioids, advancing towards pre-commercialization.

ERC Proof of...€ 150.000
2023
Details
ERC Advanced...

Uncovering the cortical cellular basis of specificity and chronicity of pain

This project aims to identify and manipulate neocortical neuronal ensembles to understand their role in pain perception and develop non-invasive methods for chronic pain relief.

ERC Advanced Grant
€ 2.468.700
2025
Details
ERC Advanced...

Descending control of pain

DescendPain aims to classify RVM neuron types and uncover how brain modulation of pain varies with affective states, potentially transforming pain treatment strategies.

ERC Advanced Grant
€ 2.500.000
2023
Details
ERC Advanced...

Engineering synthetic mechanotransduction through nucleocytoplasmic transport

This project aims to engineer synthetic mechanotransduction in cells to control gene expression through mechanical signals, enhancing our understanding of cell behavior in response to tissue mechanics.

ERC Advanced Grant
€ 2.499.875
2023
Details
ERC Consolid...

PERSONALIZED NON-INVASIVE NEUROMODULATION IN PAIN

PersoNINpain aims to personalize chronic pain treatment by using brain connectivity metrics to optimize non-invasive neuromodulation techniques like rTMS for individual patients.

ERC Consolidator Grant
€ 1.618.278
2023
Details
ERC Proof of...

Chronic PAIN eradiCAtion by taRgeting Schwann cElls

PAIN-CARE aims to develop Schwann cell selective analgesic drugs to effectively treat chronic pain with fewer side effects than current NSAIDs and opioids, advancing towards pre-commercialization.

ERC Proof of Concept
€ 150.000
2023
Details

Vergelijkbare projecten uit andere regelingen

ProjectRegelingBedragJaarActie

HB-086 and HB-097 for Treatment of Chronic Sensory Neuronal Disorders - Neuropathic Pain and Hearing Loss

HB-086 and HB-097 are therapeutic proteins targeting sensory nerve cells to treat chronic pain and hearing loss, demonstrating significant pain relief and hearing preservation in preclinical models.

EIC Accelerator€ 2.325.312
2022
Details

PN6047 - a breakthrough treatment of neuropathic pain

PharmNovo aims to advance PN6047, a selective delta opioid receptor agonist for neuropathic pain, through Phase IIa trials to confirm efficacy and attract investment for further development.

EIC Accelerator€ 2.493.000
2024
Details
EIC Accelerator

HB-086 and HB-097 for Treatment of Chronic Sensory Neuronal Disorders - Neuropathic Pain and Hearing Loss

HB-086 and HB-097 are therapeutic proteins targeting sensory nerve cells to treat chronic pain and hearing loss, demonstrating significant pain relief and hearing preservation in preclinical models.

EIC Accelerator
€ 2.325.312
2022
Details
EIC Accelerator

PN6047 - a breakthrough treatment of neuropathic pain

PharmNovo aims to advance PN6047, a selective delta opioid receptor agonist for neuropathic pain, through Phase IIa trials to confirm efficacy and attract investment for further development.

EIC Accelerator
€ 2.493.000
2024
Details

SubsidieMeesters logoSubsidieMeesters

Vind en verken subsidieprojecten in Nederland en Europa.

Links

  • Projecten
  • Regelingen
  • Analyses

Suggesties

Heb je ideeën voor nieuwe features of verbeteringen?

Deel je suggestie
© 2025 SubsidieMeesters. Alle rechten voorbehouden.